Exabis Library
Welcome to the e-CCO Library!
P063: Faecal calprotectin as a non-invasive treatment target to predict mucosal healing and histological remission in asymptomatic ulcerative colitis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P063: HDAC as versatile regulators of the intestinal epithelial barrier in inflammatory bowel disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P063: Host-mycobiome interactions during the resolution of inflammation in experimental colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:48 AM
P063: Representative and comprehensive analysis of colonic and ileac biopsies from IBD patients by gene expression profiling using the straightforward, fast, and affordable novel application Whole Transcriptome AmpliSeq on the Ion Torrent NGS platform
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P063: The immunological landscape of intestinal fibrosis in Crohn’s Disease.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P064 Exosomes from mesenchymal stromal cells reduce murine colonic inflammation via a macrophage-dependent mechanism
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P0640: Development and characterization of LQ080x7x7x7 a novel extended half-life bispecific TL1A/IL-23 p19 single domain antibody for the treatment of IBD
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0641: Efficacy of Vedolizumab and Ustekinumab Following Cyclosporine Induction in Acute Severe Ulcerative Colitis: A Retrospective Cohort Study.
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0642: Assessment of the real-world effectiveness of upadacitinib in patients with moderate-severe ulcerative colitis in a global real-world setting
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0643: Development of a personalized infliximab dosing algorithm for Acute Severe Ulcerative Colitis: results of a multi-center pharmacometrics analysis
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0645: CDAI underestimates disease activity in overweight patients with Crohn’s Disease when compared to endoscopic assessment
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0646: Significant mental health and fatigue burden found in tertiary paediatric IBD service in Australia
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0647: Impact of Age and Comorbidities on Treatment Outcomes and Mortality in Patients Admitted for Ulcerative Colitis Flares: A 20-Year Retrospective Cohort Study
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0648: The Safety and Effects of a Dual-Strain Probiotic Versus Placebo on Fatigue in Patients with Ulcerative Colitis
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0649: Acceptability and Tolerance of Risankizumab Treatment Administered via On-Body Injector in Patients with Crohn’s Disease: Results of the Nationwide ACCEPT-OBI Study
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P064: 3-oxo-C12:2, a Quorum Sensing molecule from the gut, exerts anti-inflammatory effects through a bitter taste receptor
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P064: EBI2 and oxysterols in the development of intestinal lymphoid structures and colitis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P064: High intestinal Secretory Leukocyte Protease Inhibitor (SLPI) expression correlates with abundant neutrophilic inflammation and identifies Inflammatory Bowel Disease patients with a strong IL-17 response.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:48 AM
P064: IMU-838, a Small Molecule DHODH Inhibitor in Phase 2 Clinical Trial for Ulcerative Colitis, Shows Potent Anti-inflammatory Activity in Cell-Culture-Based and In Vivo Systems
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P064: Intestinal expression of LAG-3 correlates with inflammatory activity and response to biological therapy in ulcerative colitis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM